Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1350 - Ranibizumab for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO)

Assessment No

1350
Application NameRanibizumab for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO)
Assessment TypeTBC by the applicant
Description of Medical ServiceThis service is for use of optical coherence tomography in the diagnosis and monitoring of treatment with ranibizumab in patients with retinal vein occlusion.
Description of Medical ConditionRVO is the second most sight-threatening retinal vascular disease after diabetic retinopathy. If untreated, RVO does not resolve in the majority of patients but results in visual impairment and significant ocular complications. RVO is not a chronic condition; it is an acute event that causes reduced retinal perfusion, retinal ischaemia and increased production of vascular endothelial growth factor (VEGF). Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A) and is considered a treatment option.
Pre Assessment Meeting-
Stage 2 – Suitability for Assessment14 February 2013
Stage 6 – MSAC Appraisal5 April 2013
Stage 6 – MSAC Advice-
Stage 7 – Noting by Minister-
Stage 8 – Implementation-

Page currency, Latest update: 05 November, 2014